Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 114-118

  Alexander Jr , H Richard ^a   Fraker, Douglas L ^a   Bartlett, David L ^a   Libutti, Steven K ^a   Steinberg, Seth M ^a   Soriano, Perry ^a   Beresnev, Tatiana ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLISTER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IN-TRANSIT METASTASIS; ISOLATED LIMB PERFUSION; LEUKOPENIA; LIMB PERFUSION; LIMB TUMOR; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUSCLE WEAKNESS; MYALGIA; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROPERITONEAL HEMORRHAGE; SEX DIFFERENCE; SKIN BIOPSY; SKIN TOXICITY; SURGICAL MORTALITY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR VOLUME; METHODOLOGY; MIDDLE AGED; MORTALITY; REGIONAL PERFUSION;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 73949133664     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.7511     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Slingluff CL, Flaherty K, Rosenberg SA, et al: Cutaneous Melanoma, in DeVita VT, Lawrence TS, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 8). Philadelphia, PA, Lippincott, 2008, pp 1897-1951
3. Creech O, Krementz ET, Ryan RF, et al: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 148:616-632, 1958
4. Alexander HR: Isolation perfusion, in DeVita VT, Lawrence TS, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 8). Philadelphia, PA, Lippincott, 2008, pp 701-707
5. Thom AK, Alexander HR, Andrich MP, et al: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. J Clin Oncol 13:264-273, 1995
6. Stam TC, Jongen-Lavrencic M, Eggermont AMM, et al: Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer. Eur J Clin Invest 26:1085-1091, 1996
7. Vrouenraets BC, Kroon BB, Ogilvie AC, et al: Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 6:405-412, 1999
8. Zogakis TG, Bartlett DL, Libutti SK, et al: Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 8:771-778, 2001
9. Stam TC, Swaak AJG, de Vries MR, et al: Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-α complicated by high leakage. Ann Surg Oncol 7:268-275, 2000
10. Lienard D, Ewalenko P, Delmotti JJ, et al: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60, 1992
11. Knorr C, Meyer T, Janssen T, et al: Hyperthermic isolated limb perfusion (HILP) in malignant melanoma: Experience with 101 patients. Eur J Surg Oncol 32:224-227, 2006
12. Grunhagen DJ, de Wilt JH, van Geel AN, et al: TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 31:1011-1019, 2005
13. Libutti SK, Alexander HR, Bartlett DL, et al: Patterns of local failure in extremity melanoma after a complete response to isolated limb perfusion with melphalan with or without tumor necrosis factor. Proc Am Soc Clin Oncol 15:552, 1996
14. Bartlett DL, Ma G, Alexander HR, et al: Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 80:2084-2090, 1997
15. Cornett WR, McCall LM, Petersen RP, et al: Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020. J Clin Oncol 24:4196-4201, 2006
16. Klaase JM, Kroon BBR, van Geel AN, et al: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion using melphalan. Surgery 115:39-45, 1994
17. Fraker DL, Alexander HR, Andrich M, et al: Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1:122-130, 1995
18. Luck JM: Action of p-dichloroethyl amino-L-phenylalanine on Harding-Passey mouse melanoma. Science 123:984-985, 1956